Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  OptiNose, Inc.    OPTN

OPTINOSE, INC.

(OPTN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Optinose Announces Departure of Chief Commercial Officer

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/17/2019 | 04:01pm EDT

YARDLEY, Pa., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the departure of its Chief Commercial Officer, Tom Gibbs.

Mr. Gibbs will be leaving the Company next week to assume a senior general management role at a major multinational pharmaceutical company. Senior members of the Optinose commercial leadership, including Vice Presidents of sales, marketing, and market access, will report directly to Optinose President and Chief Operating Officer Ramy Mahmoud on an interim basis as the Company initiates a search for a Chief Commercial Officer.

"Our entire company would like to thank Tom for his outstanding contributions over the past three years,” said Ramy Mahmoud, MD, MPH. “Tom has become a good friend and has been valuable in helping us build and grow an experienced and talented commercial team. We all wish him continued success in future.”

Chief Executive Officer Peter Miller added “Ramy and I work closely with Tom and the commercial leadership team every day and have great confidence in continued strong execution of the XHANCE® launch strategy that has proven so successful in growing our business. Together we have developed and executed a commercial strategy for XHANCE that has produced three consecutive quarters of 50% or greater prescription growth and that we expect will produce net revenues for 2019 in the range of $29 to $34 million.”

“Working with Peter, Ramy and the team at Optinose to successfully launch XHANCE has been one of the greatest and most fulfilling accomplishments in my career,” said Tom Gibbs, departing Chief Commercial Officer. “XHANCE performance over the last three quarters has been very strong, and I believe the underlying business fundamentals for XHANCE remain strong. I look forward to following the team’s success as they continue to build a leading ENT and allergy company.”

About Optinose
Optinose is a specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. Optinose has offices in the U.S., the U.K. and Norway. To learn more, please visit www.optinose.com or follow us on Twitter and LinkedIn.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this purpose and include, among others: projected XHANCE net revenues for 2019; continued strong future execution of the XHANCE launch strategy; XHANCE business fundamentals; and other statements regarding the Company's future operations, financial performance, financial position, prospects, objectives and other future events. Forward-looking statements are based upon management’s current expectations and assumptions and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: the Company’s ability to grow XHANCE prescriptions; physician and patient acceptance of XHANCE; the Company’s ability to maintain adequate third-party reimbursement for XHANCE (market access); market opportunities for XHANCE may be smaller than expected; and the risks, uncertainties and other factors discussed under the caption "Item 1A. Risk Factors" and elsewhere in the Company’s most recent Form 10-K and Form 10-Q filings with the Securities and Exchange Commission - which are available at www.sec.gov. As a result, you are cautioned not to place undue reliance on any forward-looking statements. Any forward-looking statements made in this press release speak only as of the date of this press release, and the Company undertakes no obligation to update such forward-looking statements, whether as a result of new information, future developments or otherwise.

Optinose Investor Contact
Jonathan Neely
jonathan.neely@optinose.com
267.521.0531

 

Primary Logo


© GlobeNewswire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on OPTINOSE, INC.
10/04OPTINOSE : Appoints Michael Richardson to New Position of Vice President, Busine..
AQ
10/04Optinose Appoints Michael Richardson to New Position of Vice President, Busin..
GL
09/27Optinose to Present at the 2019 Cantor Global Healthcare Conference
GL
09/26OPTINOSE, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
09/26OptiNose Announces License Agreement Related to ONZETRA XSAIL
GL
09/17OPTINOSE, INC. : Change in Directors or Principal Officers, Regulation FD Disclo..
AQ
09/17Optinose Announces Departure of Chief Commercial Officer
GL
09/12OPTINOSE, INC. : Entry into a Material Definitive Agreement, Termination of a Ma..
AQ
09/12Optinose Announces $150 Million Debt Financing from Pharmakon
GL
08/12OPTINOSE : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESUL..
AQ
More news
Financials (USD)
Sales 2019 31,7 M
EBIT 2019 -105 M
Net income 2019 -114 M
Debt 2019 -
Yield 2019 -
P/E ratio 2019 -2,73x
P/E ratio 2020 -3,79x
Capi. / Sales2019 9,76x
Capi. / Sales2020 3,90x
Capitalization 309 M
Chart OPTINOSE, INC.
Duration : Period :
OptiNose, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OPTINOSE, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 23,40  $
Last Close Price 7,46  $
Spread / Highest target 262%
Spread / Average Target 214%
Spread / Lowest Target 168%
EPS Revisions
Managers
NameTitle
Peter Kaighn Miller Chief Executive Officer & Director
Ramy A. Mahmoud President & Chief Operating Officer
Joseph C. Scodari Independent Chairman
Keith Alan Goldan Chief Financial Officer
John C. Messina SVP-Clinical Development & Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
OPTINOSE, INC.20.32%309
IQVIA HOLDINGS INC.23.52%28 109
LONZA GROUP32.98%25 271
CELLTRION, INC.--.--%19 657
INCYTE CORPORATION22.28%16 724
SEATTLE GENETICS, INC.54.25%14 852